T-cadherin (T-cad) promotes survival, proliferation, and migration of endothelial cells and induces angiogenesis. We aimed to identify domains of T-cad functionally relevant to its effects on endothelial cell behavior. To specifically target the functional properties of the 5 cadherin repeat domains (EC1-EC5) of T-cad, endothelial cells were transduced with lentivectors containing specific T-cad-domain-deletion mutant constructs (⌬I, ⌬II, ⌬III, ⌬IV, ⌬V). Empty (E) lentivector-transduced cells served as control. Similarly to overexpression of native T-cad, cells expressing ⌬II, ⌬III, or ⌬IV displayed elevated levels of p-Akt and p-GSK3␤ and increased proliferation rates (for ⌬II, ⌬III) vs. E. ⌬I-and ⌬V-transduced cells exhibited reduced levels of p-Akt and p-GSK3␤ and retarded growth rates vs. E. Stimulatory effects of native T-cad overexpression on Akt and GSK3␤ phosphorylation were dose dependently inhibited by coexpression of ⌬I or ⌬V. Subsequent functional analyses compared only ⌬I-, ⌬II-, and ⌬V-mutant constructs with E as a negative control. Unlike ⌬II cells, ⌬I and ⌬V cells failed to exhibit homophilic ligation and deadhesion responses on a substratum of T-cad protein. In the wound assay, migration was increased for ⌬II cells but impaired for ⌬I and ⌬V cells. In endothelial cell-spheroid assay, angiogenic sprouting was augmented for ⌬II cells but inhibited for ⌬I and ⌬V cells. We conclude that EC1 and EC5 domains of T-cad are essential for its proangiogenic effects. ⌬I and ⌬V constructs may serve as dominant-negative mutants and as potential tools targeting excessive angiogenesis.-Joshi, M. B., Kyriakakis, E., Pfaff, D., Rupp, K., Philippova, M., Erne, P., Resink, T. J. Extracellular cadherin repeat domains EC1 and EC5 of T-cadherin are essential for its ability to stimulate angiogenic behavior of endothelial cells. FASEB J. 23, 000 -000 (2009). www.fasebj.org
It has long been recognized that a great number of pathological conditions are associated with a component of either excessive angiogenesis (e.g., atherosclerotic plaque instability, solid tumor growth, psoriasis, rheumatoid arthritis) or insufficient angiogenesis (e.g., peripheral, cerebral, and myocardial ischemia/infarct) (1) . Accordingly, much effort has been devoted to identifying target molecules that can be exploited for therapeutic strategies aimed at inhibiting or promoting angiogenesis (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
T-cadherin (T-cad) is a unique member of the type 1 cadherin family of adhesion molecules. Mature T-cad shares the 5 extracellular cadherin repeat (EC1, EC2, EC3, EC4, and EC5) domain structure but lacks the transmembrane and cytosolic domains and attaches to the membrane via a glycosylphosphatidylinositol (GPI) anchor (13, 14) . A variety of functions have been attributed to T-cad, including negative guidance of neural cells, regulation of tumor cell proliferation, and regulation of vascular cell phenotype [reviewed by Philippova et al. (14) ]. T-cad is abundantly expressed in the vasculature, and accumulating data support a facilitatory role in the progression of pathological conditions associated with neovascularization. Up-regulation of T-cad has been shown to occur in vivo on vascular cells during atherosclerosis (15) and restenosis (16) and on endothelial cells from neovessels in lung metastases of different tumors (17) and metastatic hepatocellular carcinoma (18, 19) . Expression of T-cad in cultures of smooth muscle or endothelial cells correlated with cell-cycle progression and proliferation status (16, 20) . Exposure of endothelial cells to conditions of oxidative stress caused an up-regulation of T-cad that functions to protect against stress-induced apoptosis (21, 22 ). Overexpression and/or homophilic ligation of T-cad molecules by recombinant T-cad protein or agonistic antibody in endothelial and smooth muscle cells induced a more polarized, motile phenotype and promoted cell migration (23, 24) . In addition, T-cad overexpression and/or ligation were shown to promote angiogenesis in vitro using a variety of 2-D and 3-D models (25, 26) and in vivo using a model of myoblastmediated gene transfer to mouse skeletal muscle (25) . Use of null T-cad mice confirmed proangiogenic properties for T-cad in vivo; T-cad ablation limited neovascularization and resulted in reduced tumor growth in the mammary tumor (MMTV)-polyoma virus transgenic model (but concomitantly increased pulmonary metastases) (27) .
Since T-cad can affect angiogenic behavior of endothelial cells bidirectionally [i.e., up-regulation of T-cad is proangiogenic (25, 26) , whereas down-regulation is antiangiogenic (27) ], it represents an interesting therapeutic target for proangiogenic and antiangiogenic strategies. Inducible gene therapy using dominant negative mutants of T-cad may be a novel approach to reduce pathological angiogenesis. To this end, it is necessary to identify domains in T-cad protein that are functionally relevant to its effects on the angiogenic behavior of endothelial cells. In this study, we generated an array of lentiviral vectors carrying specific T-cad-deletion mutant constructs, each missing one of the 5 EC domains, and examined behavioral consequences in transduced endothelial cells. We demonstrate that domains EC1 and EC5 are essential for T-cad-dependent intracellular signaling, deadhesion, proliferation, migration, and angiogenesis in vitro.
MATERIALS AND METHODS

Cell culture
Human umbilical vein endothelial cells (HUVECs) were maintained in endothelial cell growth medium (ECGM) consisting of basal endothelial cell medium and low serum (2%) endothelial cell growth supplement mix (PromoCell GmbH., Heidelberg, Germany). Human microvascular endothelial cell (HMEC-1) line (28) was maintained in ECGM with further addition of FCS to a final concentration of 10%. D10 melanoma cell line was maintained in DMEM containing 10% FCS.
Construction of mutants
All primers and oligos were purchased from Microsynth (Balgach, Switzerland). A DNA segment (63 bp) coding for leader peptide enabling transport of protein from Golgi bodies to membrane was synthesized with NheI and BamHI restriction sites at the 5Ј and 3Ј ends, respectively. DNA coding for each of the extracellular domains (EC1-EC5) of mature T-cad was amplified using sets of forward and reverse primers incorporated with nucleotides for restriction sites BamHI and KpnI, respectively. Human T-cad cDNA cloned in plasmid pcDNA3 was used as a template. A DNA fragment (63 bp) coding for GPI anchoring to protein was synthesized with KpnI and AflII restriction sites at the 5Ј and 3Ј ends, respectively. Leader peptide, selected EC domains, and GPI anchoring signal DNA segments were ligated using DNA ligase to obtain final mutant constructs. Full-length T-cad and the T-cad-mutant constructs with deletion of either EC1 (⌬I), EC2 (⌬II), EC3 (⌬III), EC4 (⌬IV), or EC5 (⌬V) were cloned into pShuttle vector in between the NheI and AflII restriction sites. Finally, full-length T-cad and T-cad-deletion mutants were subcloned into pWPXL lentiviral vector (Tronolab, Lausanne, Switzerland) in between MluI and SmaI restriction sites after excision of GFP gene, as schematically represented (for any given construct) in Fig. 1A . Sequences of primers are available on request. Plasmids pCMV-dR8.91 and pMD2.G-VSVG (Tronolab) were used as packaging system and envelope plasmid, respectively.
Production and titration of lentiviral particles and expression of mutant proteins
Lentiviral particles were propagated in HEK 293T cells using the calcium phosphate method (22). Titration of viral particles was performed using the Quick Titer lentivirus titer kit (Cell Biolabs, San Diego, CA, USA), which measures lentivirus-associated HIV p24 by ELISA. Viral genome copy number after incorporation of lentiviral constructs into genome was estimated by RT-PCR using primers specific to lentiviral genes. To calculate amount of infectious units, p24 titer was correlated to viral genome copy number normalized to GAPDH gene. Target cells were seeded at a density of 1.5 ϫ 10 5 cells/well in a 6-well plate 24 h prior to transduction (22). Unless otherwise specified, for functional assays, transduced cells were passaged into the appropriate culture vessel 48 h post-transduction. Expression of mutant proteins in target cells was routinely controlled by immunoblotting.
Immunoblotting
The method of immunoblotting has been described previously (21, 29) . Samples (5-10 g/lane) were electrophoresed on 8% SDS-PAGE under reducing conditions. Primary antibodies used included custom-generated rabbit antibodies against either the first (anti-EC1) or the fifth (anti-EC5) extracellular domains of human T-cad (15); goat anti-human T-cad antibodies (R&D Systems Europe, Abingdon, UK); rabbit anti-Akt, anti-phospho-(Ser-473)Akt, anti-GSK3␤, antiphospho-(Ser-9)GSK3␤ (Cell Signaling, New England Biolabs GMBH, Frankfurt, Germany); rabbit anti-GAPDH (Abcam, Cambridge, UK); and rabbit anti-␤-actin (Santa Cruz Biotechnology, Heidelberg, Germany). Secondary HRP-conjugated anti-species IgGs were from Southern Biotechnology (BioReba AG, Reinach, Switzerland). Amersham ECL (Amersham Biosciences, Little Chalfont, UK), Pierce ECL, or Pierce SuperSignal West Dura (Pierce, Rockford, IL, USA) were variously used for detection of immunoreactive proteins. Scanned images of autoradiograms were analyzed using AIDA Image software (Raytest, Straubenhardt, Germany).
Biotinylation of surface proteins
HMEC-1s were washed twice with cold PBS containing Ca 2ϩ and Mg 2ϩ and then membrane surface proteins labeled by incubation of cells with 1.5 mg/ml impermeant LC-sulfo-NHS-(ϩ)-biotin (Molecular BioSciences; Socochim SA, Lausanne, Switzerland) for 30 min at 4°C. Cells were washed twice for 20 min with ice-cold 100 mM glycine in PBS, twice with ice-cold PBS, and then lysed for 2 h at 4°C with buffer containing Tris-HCl 50 mM (pH 8.0), 100 mM NaCl, 5 mM CaCl 2 , 0.2% SDS, 1% Triton X-114, and complete Mini protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Biotinylated proteins were adsorbed onto streptavidin-agarose beads (Sigma-Aldrich, Buchs, Switzerland), and after elution by heating at 95°C with SDS-PAGE sample buffer, eluates were analyzed by immunoblotting for the presence of T-cad protein using goat anti-human T-cad antibodies.
Adhesion
Adhesion of HMEC-1s onto a substratum of T-cad protein was performed essentially as described before (23) . HMEC-1s were detached by incubation in buffer containing 1 mM EDTA, 126 mM NaCl, 5 mM KCl, and 50 mM HEPES (pH 7.4) (30) and seeded into 96-well plates (5ϫ10 3 cells/well) precoated overnight at 4°C with containing 10 g/ml recombinant T-cad protein (23) or 10 g/ml BSA. Adhesion onto these substrata was quantified at selected intervals thereafter by rinsing wells with PBS to remove nonadherent cells and subsequent enumeration of adherent cells by enzymatic (0.1% trypsin/1 mM EDTA in PBS) detachment and counting in a Coulter counter.
Proliferation
HMEC-1s were seeded into 96-well plates (3ϫ10 3 cells/well), and cell proliferation was monitored daily for 4 d by cell enumeration after trypsinization and counting in a Coulter counter.
Wound assay and time-lapse videomicroscopy
After scrape-wounding, confluent monolayer cultures of HMEC-1 wound closure were filmed at a rate of 1 frame/15 min, for up to 12 h using an Olympus IX-81 inverted time-lapse microscope equipped with a digital camera (Olympus, Tokyo, Japan) within a humidified incubation chamber with 5% CO 2 at 37°C. Acquired images were processed and analyzed using CellR software (Soft Imaging System, Muenster, Germany). Each experiment contained parallel wells for every experimental condition. Three different fields of observation at the initial wound front (time 0) were randomly selected and fixed, and the distance of cell migration into the wound area was measured every 15 min. Every 60 min, a data point for path length was calculated as the average path length from 4 consecutive 15-min frames.
Spheroid assay of angiogenesis in vitro
Endothelial cell spheroid assay in 3-D collagen or fibrin gels was performed as described previously (25) . Spheroids were composed of 500 endothelial cells, each gel contained ϳ30 spheroids, and incubation was under normoxic conditions for 24 h. For microscopic visualization of spheroids, in-gel fixation and staining with TRITC-conjugated phalloidin (0.5 g/ml; Sigma-Aldrich) were performed. Outgrowth of capillary-like structures from spheroids was evaluated by morphometric analysis of the number and total length of sprouts per spheroid, using AnalySIS software (Soft Imaging System). At least 20 spheroids from two parallel wells were analyzed for each experimental point.
Statistical analysis
All experiments were performed on Ն3 separate occasions. Results are given as means Ϯ sd unless otherwise stated. Statistical significance was determined using 2-tailed Student's t test with Prism 5.0 software (GraphPad Software, San Diego, CA, USA). A value of P Ͻ 0.05 was considered significant.
RESULTS
Expression of T-cad-domain-deletion mutants in endothelial cells
To identify the functional relevance of the cadherin repeat domains EC1-EC5 of T-cad, we constructed 5 T-cad-deletion mutants, each lacking one of the domains. Figure 1A depicts the basic cloning strategy for any given mutant construct with insertion into pWPXL lentiviral vector. Figure 1B illustrates the domain composition of T-cad-deletion mutants ⌬I, ⌬II, ⌬III, ⌬IV, and ⌬V. Lentivector carrying full-length T-cad (T vector) was used as a positive control, and empty lentivector (E vector) served as the negative control. The expression characteristics of T-cad mutant proteins in whole-cell lysates of HMEC-1s were examined by immunoblotting (Fig. 2) . HMEC-1 express mature 105-kDa and precursor 130-kDa T-cad proteins following transduction with vector carrying full-length T-cad, as expected (21, 25, 31, 32) . Each of the T-cad-deletion mutants was expressed as two products with apparent molecular masses ranging between ϳ60 and ϳ105 kDa ( To determine cellular location of the proteins, immunoblotting was performed on cell lysates collected after a 15 min treatment of cultures with 0.1% trypsin/1 mM EDTA. The products of ⌬I (ϳ65 and ϳ105 kDa) and ⌬II (ϳ65 and ϳ75 kDa) and the highermolecular-mass forms of ⌬III (ϳ105 kDa), ⌬IV (ϳ75 kDa) and ⌬V (ϳ105 kDa) were trypsin sensitive ( Fig.  2A) , indicating translocation of these mutant proteins to plasma membrane surface. The lower-molecularmass forms of ⌬III, ⌬IV, and ⌬V (ϳ65 kDa) were trypsin insensitive, indicating a cytoplasmic localization. These results were validated by performing surface biotinylation of transduced HMEC-1s, followed by streptavidin-agarose adsorption of biotinylated proteins and subsequent immunoblotting for T-cad (Fig. 2B) .
To exclude that the ϳ105-kDa proteins expressed by mutant constructs might reflect up-regulation of endogenous mature T-cad, we performed immunoblotting on lysates from E-, T-, ⌬I-, and ⌬V-vector-transduced HMEC-1s using antibodies raised against either full-length T-cad (anti-T-cad as used in Fig. 2A ), domain EC1 (anti-EC1), or domain EC5 (anti-EC5). As shown in Fig. 2C , anti-EC1 failed to recognize mutant proteins expressed by ⌬I vector, and anti-EC5 failed to recognize mutant proteins expressed by ⌬V vector. Antibodies against domains EC2, EC3, and EC4 are not available. To further validate the identity of proteins expressed by T-cad-deletion mutants, we transduced the D10 melanoma cell line, which is negative for T-cad at both protein (Fig. 2D ) and mRNA levels (data not shown). Each of the deletion mutants was expressed in D10 cells as two products with the same molecular masses as found for HMEC-1s, albeit in different proportions.
Inhibition of N-glycosylation increases degradation susceptibility of T-cad
The T-cad-mutant constructs do not contain the precursor domain and therefore, theoretically, should express only a single protein. However, mature T-cad possesses 6 putative N-glycosylation sites (1 in EC3, 2 in EC4, and 3 in EC5) (NCBI accession no. P55290), and it is possible that domain deletion might lead to disruption of protein folding and an alteration in accessibility of different sites for glycosylation (33) , yielding differentially glycosylated products. We accordingly examined the effect of the N-glycoslyation inhibitor tunicamycin on expression of native and mutant T-cad proteins in HMEC-1s. Cells were treated with tunicamycin 4 h post-transduction and throughout a subsequent 48-h culture period. We observed an almost complete loss of immunoreactivity at the positions expected for glycosylated native mature (105 kDa) and precursor T-cad (130 kDa) proteins and a slight accumulation of Full-length T-cad-containing (T) and empty (E) lentiviral vectors served as positive and negative controls, respectively. A) Seventy-two hours after transduction, whole-cell lysates of HMEC-1s were collected before or after treatment (15 min) with 0.1% trypsin/1 mM EDTA, and subjected to immunoblot analysis for T-cad proteins using R&D anti-T-cad antibodies. Blots were probed with anti-GAPDH to control for protein loading. B) Following surface biotinylation of transduced HMEC-1s and streptavidin-agarose adsorption of proteins, cells were tested for the presence of T-cad by immunoblotting. C) Triplicate blots of lysates from E-, T-, ⌬I-, and ⌬V-transduced HMEC-1s were analyzed for T-cad immunoreactivity using R&D anti-T-cad antibodies (anti-T-cad) and antibodies raised against domain EC1 (anti-EC1) or domain EC5 (anti-EC5). a band at ϳ80 kDa (Fig. 2E) . Notably, this band was present at an equivalent intensity in E-, T-, and all deletion-mutant-transduced cells, and therefore represents an unglycosylated form of the endogenously expressed T-cad protein. The lower-and higher-molecular-mass proteins of all T-cad-domain-deletion mutants correspond to differentially glycosylated products of mutant protein, since neither band was present in tunicamycin-treated mutant-transduced cells. In addition to the presumed unglycosylated endogenous T-cad protein (ϳ80 kDa), tunicamycin-treated mutant-transduced cells accumulated a low level of a ϳ55-kDa band that most likely represents unglycosylated mutant T-cad protein.
Differential effects of T-cad-domain-deletion mutants on Akt/GSK3␤ signaling and proliferation: dominant negative action of ⌬I-and ⌬V-mutant proteins Activation of the Akt/GSK3␤ signal transduction axis is an important feature of T-cad-induced signaling in endothelial cells (21, 22, 31) . Therefore, as an initial readout for domain functionality, we investigated the effect of expression of the T-cad-domain-deletion mutants on levels of phosphorylation of Akt and GSK3␤ in HMEC-1s. Figure 3A illustrates the expected (21, 22, 31) constitutive increase in p-Akt and p-GSK3␤ in HMEC-1z transduced with full-length T-cad (increases of ϳ1.76-and ϳ1.84-fold vs. control E-transduced HMEC-1s, respectively). Compared with Etransduced cells, those transduced with ⌬II or ⌬III, and to a lesser extent ⌬IV, exhibited higher levels of p-Akt and p-GSK3␤, whereas in ⌬I-and ⌬V-transduced cells, levels of p-Akt and p-GSK3␤ were lowered by ϳ50% (Fig. 3B, C) .
We next examined the effect of expression of T-caddomain-deletion mutants on proliferation of HMEC-1s. E-transduced HMEC-1s served as the baseline control. 
Proliferation of ⌬IV-transduced cells was not different from E-transduced cells. Expression of deletion mutant ⌬I or ⌬V markedly inhibited cell proliferation. These experiments, together with the lower constitutive levels of p-Akt and p-GSK3␤ in ⌬I-or ⌬V-transduced HMEC-s1, indicate that the ⌬I-and ⌬V-deletion mutants might function in a dominant negative fashion. We tested this possibility by examining levels of p-Akt and p-GSK3␤ following cotransfection of HMEC-1s with a constant amount of full-length T-cad-expressing vector and increasing amounts of the vectors expressing ⌬I-or ⌬V-deletion mutants, or the E vector. HMEC-1s transduced with T vector or E vector served as the positive and negative controls, respectively. The results show a dose-dependent inhibition of T-cad-dependent Akt and GSK3␤ phosphorylation by ⌬I-or ⌬V-deletion mutants, and support the hypothesis that these two mutants have the potential to act as dominant-negative inhibitors of T-cad (Fig. 5) . Subsequent experiments aimed at corroborating the negative effects of expression of ⌬I-and ⌬V-mutant proteins on endothelial cell angiogenic behavior, and we compared only ⌬I-and ⌬V-transduced endothelial cells, with Eand ⌬II-transduced endothelial cells as the negative and putative positive controls, respectively.
Expression of ⌬I-and ⌬V-mutant proteins in endothelial cell homophilic ligation and deadhesion responses, migration, and sprouting
When endothelial cells are seeded onto substrata containing either BSA or recombinant T-cad protein, there is an initial increased degree of adhesion onto the latter, which is followed by detachment of the cells (23) . Figure 6 illustrates this homophilic liga- Figure 3 . Effects of expression of T-cad-domain-deletion mutants on Akt-and GSK3␤-phosphorylation in endothelial cells. HMEC-1s in 6-well plates were transduced with the different lentivectors (E, T, ⌬I, ⌬II, ⌬III, ⌬IV, or ⌬V). Cell lysates were collected 48 -72 h post-transduction and analyzed for levels of phospho-Akt (p-Akt; A, B) and phospho-GSK3␤ (p-GSK3␤; A, C). GAPDH served as the internal loading control. Parallel blots were also probed with anti-Akt or anti-GSK3␤ to exclude alterations in levels of total Akt or total GSK3␤. A) A representative blot illustrating elevated levels of p-Akt and p-GSK3␤ following overexpression of native T-cad in HMEC-1. B, C) Levels of p-Akt (B) and p-GSK3␤ (C)in cells expressing T-cad-domain-deletion mutants are calculated relative to levels in E-transduced cells. Histograms present data obtained from 4 independent experiments; blots are representative. **P Ͻ 0.01 vs. control E-transduced cells.
tion response for control E-transduced HMEC-1s. Compared with this control, and as previously reported for endothelial cells overexpressing fulllength T-cad (23), ⌬II-transduced cells exhibited an increased initial rate of adhesion and a greater subsequent detachment when seeded onto T-cad substratum ( Fig. 6; c. f. E and ⌬II). However, adhesion of ⌬I-or ⌬V-transduced cells onto a T-cad substratum was comparable to their adhesion on control BSA substratum, indicating a failure of mutant proteins to elicit a homophilic ligation response. Adhesion of E-, ⌬I-, ⌬II-, and ⌬V-transduced cells onto control BSA substratum was equivalent.
Wound assay using time lapse videomicroscopy over a period of 12 h revealed an increased rate of migration for ⌬II-transduced HMEC-1s and an impaired migration capacity for ⌬I-and ⌬V-transduced HMEC-1s compared with control E-transduced cells (Fig. 7) .
Finally, we applied the EC-spheroid assay, which has proven to be useful for analysis of active outgrowth of newly formed capillary-like sprouts within 3-D matrices (34, 35) . Compared with spheroids composed of Etransduced cells, we found that sprout outgrowth (number and length) was increased for spheroids composed of ⌬II-transduced HMEC-1s, whereas it was inhibited by ϳ50% for spheroids composed of ⌬I-or ⌬V-transduced HMEC-1s (Fig. 8A) . To verify the antiangiogenic consequences of ⌬I-or ⌬V-deletion mutant protein expression, we repeated the in vitro angiogenesis assay with primary endothelial cells using spheroids composed of E-, ⌬I-, ⌬II-, or ⌬V-transduced HUVECs.
The data show that although expression of ⌬II-mutant protein in HUVECs had only a minimal stimulatory effect on sprout outgrowth, expression of either ⌬I-or ⌬V-mutant proteins in HUVECs clearly inhibited sprout outgrowth (Fig. 8B) and as effectively as observed for HMEC-1s (Fig. 8A) .
DISCUSSION
Mature T-cad protein possesses 5 cadherin repeat domains: EC1, EC2, EC3, EC4, and EC5.
To date, there have been only two studies that have addressed T-cad-domain functionality. The first study, by Bai et al. (36) , investigated the role of EC1 and EC2 in nerve growth factor (NGF)-induced proteasomal degradation of T-cad in PC12 pheochromocytomaderived cancer cell line. The authors showed that EC1 was important for stabilization of T-cad protein, while EC2 was important for its proteasomal degradation during NGF-induced differentiation of PC12 to a neuronal phenotype. Phosphorylation of tyrosine 327 within EC2 was shown to be required for the proteasomal degradation. The second study, by Dames et al. (37) , performed an NMR characterization of the structure, dynamics, and calcium-binding properties of EC1 of T-cad. The structural data reveal several features conserved in the amino acid composition of EC1 of T-cad from different organisms, which are distinct from the EC1 domains of other type 1 cadherins. These features reduce the ability for homodimerization and might explain the very low intercellular adhesive capacity of T-cad.
The present study was initiated to identify which of the 5 cadherin repeat domains of mature T-cad are crucial to its ability to induce angiogenic behavior in endothelial cells. Initially, we compared all 5 deletion mutants with respect to their ability to stimulate phosphorylation of Akt/GSK3␤ and cell proliferation, using empty and full-length T-cad-carrying vectors as the negative and positive controls, respectively. The Akt/ GSK3␤ phosphorylation experiments revealed that ⌬II-and ⌬III-mutant proteins function at least as well as full-length T-cad, ⌬IV-mutant protein is rather feeble, while ⌬I-and ⌬V-mutant proteins are inhibitory. The proliferation experiments suggested ⌬II-mutant protein might act in a constitutively active manner; ⌬IV-mutant protein likely functions as a null mutant, while ⌬I-and ⌬V-mutant proteins might possess dominant negative activity. The latter was confirmed in coexpression experiments, whereby ⌬I-or ⌬V-mutant proteins negated the stimulatory effects of wild-type (full length) T-cad in a dose-dependent manner. Subsequently, we focused our study on establishing the potential usefulness of ⌬I-and ⌬V-mutant proteins as inhibitors of angiogenic behavior in EC and used ⌬II as the positive control. We demonstrate that domains EC1 and EC5 are independently essential for stimulation of several functional endpoints of angiogenic behavior of EC, namely deadhesion, migration, and proliferation, as well as sprouting from endothelial cell spheroids embedded in collagen or fibrin gel.
Inappropriate expression of cadherins (e.g., mutated, forced, silenced) may be accompanied by changes in expression of other endogenously expressed cadherins. For example, expression of a chimera composed of interleukin 2 receptor extracellular domain and VE-cadherin cytoplasmic tail in endothelial cells increased degradation of endogenous VE-cadherin (38) . Expression of a fusion protein composed of the extracellular domain of a nonadherent glycoprotein and the transmembrane and cytoplasmic domains of E-cadherin in MadinDarby canine kidney cell line decreased degradation of endogenous E-cadherin (39) . VE-cadherin silenced endothelial cells exhibit increased N-cadherin expression (40, 41) , while N-cadherin-silenced cells exhibit increased VE-cadherin expression (41) . In squamous carcinoma cells, forced expression of Ncad was shown to result in down-regulation of endogenous E-cad and P-cad (42) . In these cells, forced expression of desmosomal cadherin desmoglein 1 or E-cad/desmoglein chimeras decreased expression of other endogenous desmosomal cadherins desmoglein 2 and desmocollin 2, whereas E-cadherin remained unaffected (43) . On the other hand, different breast cancer cell lines continued to express their specific complement of endogenous cadherins when transfected with a different nonendogenous cadherin (44) . In our study, we did not detect alterations in expression levels of endogenous VE-cadherin, N-cadherin (data not shown), or T-cad (Fig. 2) in endothelial cells transduced with any of the mutant T-cad constructs. This supports that alterations in parameters of angiogenic behavior measured in this study are primarily related to expression of mutant T-cad proteins.
The influence of N-glycosylation inhibitor on the expression of T-cad proteins expressed by vectors carrying native-T-cad and T-cad-deletion mutants was investigated in order to gain some understanding of possible post-translational mechanisms contributing to expression of protein isoforms differing with respect to size and localization to the cell surface and/or cytosol. Protein N-glycosylation has important functions for many proteins because it affects protein folding, quality control, sorting, degradation, secretion, and bioactivities (33, 45, 46) . Like all cadherins, T-cad is a highly glycosylated molecule. T-cad possesses 8 putative N-glycosylation sites: 2 in propeptide, 1 in EC3, 2 in EC4, and 3 in EC5. While the types of N-glycan contained at these sites are completely unknown, our data suggest that the glycosylation status of T-cad can markedly influence its stability and location. Regardless of the vector used, treatment of HMEC-1s with N-glycosylation inhibitor tunicamycin led to a substantial reduction in levels of the endogenous precursor (130 kDa) and mature (105 kDa) T-cad proteins, which was accompanied by minimal accumulation of lower-molecular-mass endogenous unglycosylated T-cad proteins. Furthermore, tunicamycin prevented the accumulation of proteins expressed by the vectors carrying either native T-cad or deletion-mutant T-cad constructs, and there was only minimal accumulation of unglycosylated deletion-mutant T-cad proteins (ϳ55 kDa). These observations suggest that unglycosylated T-cad is highly susceptible to degradation, and are in accordance with recent findings that N-glycosylation of E-cadherin plays an important role in stabilizing E-cadherin (47) . It is possible that glycosylation is also important for translocation of T-cad to the membrane. Deletion of domains EC1 and EC2, which have no glycosylation sites, did not affect translocation of mutant proteins to the membrane surface. In contrast, for mutants with a deletion of EC3, EC4, or EC5 (containing 1, 2, or 3 N-glycosylation sites, respectively) only the higher-molecular-mass products (i.e., higher degree of glycosylation) were present on the cell surface. These results suggest that a specific degree and/or site of glycosylation on T-cad might be required for translocation to the membrane.
Mechanisms explaining the dominant-negative effects of ⌬I and ⌬V T-cad-mutant proteins on endothelial cell angiogenic behavior have not yet been explored. Mimicry of T-cad homophilic ligation in endothelial cells by plating cells onto immobilized recombinant soluble T-cad or agonistic antibodies against EC1 domain induces acquisition of a polarized, deadhesive, and migratory (i.e., angiogenic) phenotype (23) via RhoA/ROCK-and Rac-dependent mechanisms (24) . A further consequence of T-cad homophilic ligation as activated by anti-EC1 antibodies or antibodies against full-length T-cad is the induction of Akt phosphorylation (22). Antibodies against EC5 fail to induce the angiogenic phenotype (23) . This study has demonstrated that expression of either ⌬I-or ⌬V-mutant proteins are inhibitory to angiogenic behavior of EC, implying that EC1 and EC5 act complementarily for T-cad functionality. We hypothesize that EC1 is crucial for ligation and initiation of T-cad-induced signaling, while juxtamembrane EC5 is important for onward actuation of signal transduction. Issues to be addressed in future studies concern the function of EC1 and EC5 with respect to localization of T-cad within plasma membrane lipid raft domains and the interaction of T-cad with auxiliary membrane adaptor molecules.
Up-regulation of T-cad on endothelial cells and proangiogenic properties of T-cad have been demonstrated in a number of studies and in different angiogenic microenvironments (17, 25, 27) . Thus, inhibiting activities of T-cad might prove a useful way of delaying progression of angiogenic-facilitated diseases, such as cancer and atherosclerosis. Significant advances in the application of immunotherapy for antiangiogenic treatment of cancer have been made (reviewed in refs. 10 -12, 48) . Humanized monoclonal antibodies targeting angiogenic growth factors (Bevacizumab/Avastin) or growth-factor receptors (Sorafenib/Nexavar; Sunitinib/Sutent; Cetuximab/Erbitux; Trastuzumab/Herceptin) are examples of immu- notherapies already approved for use in the clinics. To the best of our knowledge, function-blocking anti-T-cadherin antibodies targeting either full-length T-cad or specific cadherin repeat domains have not yet been generated. If ever produced, tagging the antibodies with an endothelial specific marker for site-directed delivery to the vasculature would be necessary for antiangiogenesis therapy, because T-cad is also highly expressed on vascular smooth muscle cells (15, 16 ). An alternative modality of targeting T-cad-facilitated angiogenesis might exploit the gene transfer of dominant-negative mutants. Gene therapybased strategies for angiogenesis inhibition have attracted great interest (reviewed in refs. 8, 9). For example, intravitreal delivery of viral vector encoding angiostatin blocked angiogenesis in a murine proliferative retinopathy model (49) . Virally mediated delivery of PEX, a noncatalytic fragment of metalloproteinase 2, inhibited neovascularization in chicken chorioallantoic membranes and tumor-induced angiogenesis and tumor growth in a nude mouse model (50) . Gene transfer of a dominant-negative mutant of MCP-1 (7ND) reduced tumor angiogenesis and tumor growth of malignant melanoma in C57BL mice (51) by preventing macrophage recruitment and vascular endothelial growth factor (VEGF) production. Virally mediated expression of a VEGFR-2 dominant-negative mutant in rat glioma model impaired angiogenesis and inhibited tumor growth (52) .
An important issue to consider in the context of inhibiting T-cad function as a potential antiangiogenic therapy in cancer arises from the finding of Ranscht and colleagues (27) that T-cad gene ablation in MMTV-PyV-mT mice resulted in an inhibition of angiogenesis and tumor growth and a concomitant increased pulmonary metastasis. Because the correlation between vascular density and metastasis is very well documented, their finding was unexpected. However, and as pointed out by the researchers, it is important to recognize that their gene ablation model does not permit distinction as to whether the observed metastasis was due to a loss of T-cad function in endothelial cells (i.e., antiangiogenic, limiting blood supply to the tumor and increasing hypoxia) or to a loss of T-cad function in all the mammary tumor cells (i.e., selection for an epithelial-mesenchymal type transition). Further, whether metastasis associated with disruption of T-cad expression/function occurs in cancers other than mammary cancer has not yet been investigated. Hebbard et al. (27) proposed testing the contribution of (a loss of) epithelial expressed T-cad to metastasis by using a gain-of-function genetic model. We would propose an alternative model in which silencing of T-cad expression/function is strictly confined to the endothelial cells; this would be helpful in clarifying whether the antiangiogenic consequence of T-cad silencing in the endothelium is necessarily accompanied by increased metastasis.
CONCLUSIONS
We have demonstrated the effectiveness and inhibitory functionality of ⌬I-and ⌬V-deletion mutants with respect to angiogenic behavior of endothelial cells. We believe that the ⌬I-and ⌬V-deletion mutants might have potential as therapeutic tools targeting excessive angiogenesis. Furthermore, the array of T-cad-domain-deletion mutants generated for this study will be useful in characterizing cell-specific effects and functions of T-cad in a variety of other cell types, such as cardiomyocytes, epithelial cells, smooth muscle cells, and tumor cells. 
